Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

• Status: Active, not recruiting
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a randomized controlled study

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Mohammad Mamun Khan
• Treatments: Methotrexate; Tofacitinib

Criteria

Inclusion Criteria:1. age greater than 18 years 2. patients fulfill the ACR-EULAR classification criteria for RA 3.DAS-28 CRP more than 5.1

-

Exclusion Criteria:

1. systemic infection

2. hemoglobin less than 9 mg/dl

3. WBC <4000, neutrophil <1000, platelet <100000/mm

4. live vaccine within 3 months

5. GFR < 50 ml/min

6. ALT > 2 times ULN

7. pregnancy